DEV Community: Vishal Kumar

You Can't Build a Detector for Absence

Vishal Kumar — Tue, 18 Aug 2026 09:41:52 +0000

A failure mode with no signal

Here's a constraint that shows up in more systems than people expect, and healthcare has a clean example of it.

In medication reconciliation at hospital admission, peer-reviewed studies put omission — a drug the patient actually takes that's simply missing from the list — at roughly 76% of errors found. Incorrect dosage is a distant second around 16%. Between 39% and 50% of admitted patients have at least one unintended discrepancy depending on setting.

Now notice what's different about omission compared to every other error type:

Error	Detectable in the record?
Wrong dose	Yes — range check
Duplicate therapy	Yes — compare entries
Interaction	Yes — pairwise lookup
Contraindication	Yes — rule against diagnosis
Omission	No

Everything except omission is a function of data that exists. Omission is the absence of data. There's no outlier, no anomaly score, no rule that fires. You could run every validator you own against that record and it would pass, because the record is internally consistent. It's just incomplete, and incompleteness doesn't announce itself.

The general principle

You cannot detect absence by examining a single source. There is no signal in the thing that isn't there.

This sounds obvious stated plainly, but it gets violated constantly, because the instinct when you have a data quality problem is to build a validator over the data you have. That works for every error class except the one where the data is missing — which, here, is the majority class.

Detecting absence requires a second, independent source and a comparison. That's the only mechanism. Which means the architecture isn't "analyse the record," it's "reconcile across sources," and those are very different systems.

Why merge-and-dedupe is the wrong build

The tempting version: pull the hospital list, pharmacy fill history, last discharge summary, specialist notes. Merge. Dedupe. Return a clean unified list.

This fails for a reason worth internalising: merging is a resolution operation, and resolution destroys the finding.

When the pharmacy shows a statin filled 90 days ago and the hospital list omits it, a merge has to pick a winner. But "which source is right" isn't a data question here — it's an unestablished clinical fact. Did the patient stop? Did a specialist discontinue it? Did nobody ask? Different answers, different actions. The moment you auto-resolve, you've thrown away the only thing that was actually valuable: the knowledge that sources disagree.

Corollary: absence is ambiguous in a way presence isn't. A drug missing from a list can mean discontinued, never prescribed, prescribed elsewhere, or not mentioned during a rushed intake. Four meanings, one identical-looking gap. No amount of cleverness distinguishes them from the data alone.

What to build instead

Model it as a disagreement engine, not a merger:

Represent SOURCES_DISAGREE as a first-class state. Not an error, not something to reconcile away — an output. Your schema should be able to say "pharmacy asserts X, hospital list is silent, unresolved."
Retain provenance per assertion. Every fact carries which source claimed it and when. You'll need this the moment anyone asks why a discrepancy was flagged.
Rank by consequence, not confidence. A missing anticoagulant and a missing vitamin D are not the same finding. Reviewer attention is the scarce resource; spend it by clinical weight.
Route to someone who can resolve it out-of-band. Some of these are only answerable by asking the patient. Design for that as the terminal step rather than pretending the system can close the loop itself.

Same shape as the four-state evaluation I wrote about last time — UNKNOWN deserves to be a value, not a default to NO.

The honest boundary

An agent cannot confirm a medication list. Confirmation requires a clinician or pharmacist talking to the patient. Also worth stating: pharmacy fill data shows dispensing, not adherence — a filled prescription means it was collected, not that it's being taken. And I'm not claiming this reduces adverse drug events; that needs outcome evidence I don't have. The narrow claim: a discrepancy never surfaced is never investigated.

We build this pattern at IntelliBooks Studio. Happy to get into the provenance schema or the disagreement-state modelling in the comments.

Matching Prose to Prose: Why Unknowns Beat Confidence Scores

Vishal Kumar — Mon, 17 Aug 2026 09:28:57 +0000

The problem shape

Clinical trial patient matching is a good case study in a class of problem that shows up constantly and gets modelled wrong: matching prose against prose, where the cost of a false positive and a false negative are wildly different.

A trial protocol's eligibility section says things like:

No prior systemic therapy for metastatic disease. ECOG performance status 0–1. Adequate hepatic function.

Those are conditions, not fields. "Adequate hepatic function" expands into lab thresholds defined elsewhere in the same 40-page document. Meanwhile the evidence that answers them is split across structured data (labs, diagnosis codes, meds) and clinician notes:

...tolerated first-line well, though notes ECOG appears stable at 1. Path report pending re-review.

That sentence probably answers a criterion. No SQL query finds it.

Why "just embed everything" underperforms

The tempting move is to embed the protocol and the chart and check similarity. It works badly, for a specific reason: eligibility is conjunctive and includes negations. A patient who matches 9 of 10 criteria and fails the 10th is not a 90% match, they're ineligible. Cosine similarity has no opinion about that.

What works better is decomposing the protocol into individual criteria first, then evaluating each one separately against retrieved evidence. Slower, more calls, dramatically more useful — because now you can say which criterion failed, which is the thing a human actually needs.

Unknowns are first-class results

The design decision that mattered most for us: a criterion evaluates to one of four states, not two.

MET — evidence found supporting it
NOT_MET — evidence found contradicting it
UNKNOWN — no evidence either way in the record
STALE — evidence exists but is outside a clinically relevant window

Most systems collapse UNKNOWN into NOT_MET and silently discard candidates. That's the expensive mistake. "ECOG not documented in the last 90 days" is not a rejection — it's a five-minute task for a coordinator that might surface an eligible patient. Merging unknown into no throws away exactly the cases where a human adds the most value.

Corollary: don't emit a single confidence score. A 0.73 tells a reviewer nothing actionable. A per-criterion breakdown with the source sentence quoted tells them precisely where to look. Scores are for ranking the queue; the breakdown is what makes review possible.

Retrieval is per-criterion, not per-patient

Naive version: retrieve "the patient's record" and evaluate all criteria against it. This blows context and buries evidence.

Better: each criterion drives its own retrieval. The ECOG criterion searches for performance-status mentions; the prior-therapy criterion searches treatment history. Same patient, different retrievals, each scoped to what that condition needs. Costs more calls, and the precision difference is not close.

Asymmetric costs shape the whole design

False positive: a coordinator spends twenty minutes reviewing someone ineligible. Annoying, recoverable, and it's exactly the job.
False negative: a patient who might have qualified is never seen by anyone. Invisible, unrecoverable, and nobody ever learns it happened.

So the system should be tuned to over-surface with evidence attached, not to be precise. That inverts the usual instinct to optimize precision, and it's correct here.

The hard boundary

The agent screens; it does not determine eligibility. A coordinator or clinician confirms every candidate, and nothing enrolls anyone. In a research context the audit trail is also load-bearing rather than decorative — an IRB or sponsor asking "how were these candidates identified?" needs a better answer than "the model suggested them."

We build this pattern at IntelliBooks Studio. Happy to get into the criterion decomposition or the four-state evaluation model in the comments.

Building a Durable 30-Day Outreach Cadence (Harder Than It Sounds)

Vishal Kumar — Fri, 07 Aug 2026 09:19:56 +0000

The setup

Post-discharge follow-up reduces hospital readmissions — this is settled, and Medicare reimburses it through Transitional Care Management codes. Yet fewer than 10% of eligible beneficiaries received TCM after discharge (9.3%, per 2016 figures). Meanwhile about 75% of hospitals in the CMS readmissions program are paying penalties this year.

It's not a belief problem. Somebody has to contact thousands of people on a schedule and pay attention to the answers, and nobody has the staff. That's a throughput problem, which makes it an interesting systems problem.

Here's what building the outreach cadence actually involves. It looks trivial until you write it.

Why "just schedule some messages" fails

The naive version is a cron job that fires messages at day 2, 7, 14, 25. It breaks immediately:

The schedule is per-patient, not global. Day 2 is relative to that discharge. You're not running one schedule, you're running N concurrent stateful schedules that each started at a different wall-clock time.
Patients reply whenever. A reply to the day-7 message may land on day 9. Your state machine has to accept out-of-order input and still know where it is.
A reply can change the whole plan. "I'm short of breath" should abandon the remaining cadence and escalate. A branch mid-sequence, not at the start.
Non-response is a signal, not an absence. Silence needs retry, then escalation to human outreach. Doing nothing is the one wrong answer.
It has to survive a deploy. These sequences run for 30 days. Any in-memory state is gone the first time you ship on a Tuesday.

That last one is the real constraint and it drives everything else.

Durable state, not in-process timers

The whole thing has to be Postgres-authoritative. Each patient's sequence is a row with its position, next-action timestamp, and accumulated responses. A scheduler wakes up, queries what's due, and acts. setTimeout and in-memory queues are disqualified — not because they're inelegant but because a 30-day workflow will outlive dozens of restarts.

The corollary is that every step must be idempotent. Your scheduler will occasionally process the same due item twice (crash between action and state-write, at-least-once delivery, retries). Sending a heart failure patient the same check-in twice is a bad experience; escalating them to a nurse twice is worse. Every action needs a natural dedupe key and a check before it fires.

Response triage is a routing problem, not an NLP problem

It's tempting to treat inbound replies as a language-understanding challenge. Mostly they aren't. The structure that works:

Ask closed questions. "Has your weight gone up more than 3 pounds since you got home? Yes/No" is answerable by SMS and by a state machine. Open-ended "how are you feeling?" produces text nobody can route.
Classify against a clinician-defined rubric, not a general-purpose sentiment model. The thresholds are a clinical governance decision and belong to the health system — you're implementing their rule, not inventing one.
Escalate with the whole context attached. A nurse getting "patient reports swelling" and having to go look everything up is barely better than nothing. The escalation should carry the answers, the trend across prior check-ins, and the discharge summary.
Fail toward the human. Anything the classifier is unsure about goes to a person. The asymmetry is obvious: an unnecessary nurse review costs minutes, a missed decompensation costs an admission.

The scheduling primitives you end up needing

Working through this, the cadence engine needs roughly:

Per-entity schedules with relative anchors (t+2d from a discharge event, not a fixed date)
Branch — a response routes to a different subsequent path
Skip — a completed follow-up appointment cancels the remaining appointment-nagging steps
Fan-in — several signals (no response + missed appointment) combine into one escalation rather than three
Cancellation — readmission or death must halt the sequence immediately, and yes, you have to handle that case explicitly and carefully

If that list looks like a workflow DAG, it is. We ended up building it as one in our routines engine rather than as a message scheduler, because "sequence of timed sends" is the wrong abstraction the moment responses can alter the path.

What the agent can't do

Worth stating plainly since this is care delivery: an agent cannot deliver or bill TCM. That requires a provider's face-to-face visit. What it does is extend reach — more eligible patients enter a follow-up pathway at all, and concerning cases reach a clinician sooner. The outcome research on TCM describes human-delivered care, and I'm not claiming an automated cadence reproduces it.

We build this pattern at IntelliBooks Studio. Happy to get into the idempotency keys or the DAG state model in the comments.

Designing Human Review for Someone Who Wasn't There

Vishal Kumar — Thu, 06 Aug 2026 08:53:25 +0000

A result worth studying

Ambient AI scribes are one of the few healthcare AI categories with peer-reviewed outcome evidence. A multicenter quality-improvement study in JAMA Network Open (Oct 2, 2025) followed 263 clinicians across six health systems for 30 days: burnout dropped from 51.9% to 38.8%, with significant improvements in cognitive task load, after-hours documentation time, and focused attention on patients.

I don't build ambient scribes — I work on back-office healthcare agents (claims, prior auth, denials). But that result is worth taking apart, because three of the four things that made it work port directly, and the fourth one is a trap.

The three that port

1. It targeted something measurable. After-hours documentation time, not "productivity." You can count it before and after. If your success metric is vibes, you will not be in anyone's 5%.

2. It ran inside the existing workflow. The scribe listens during the visit. No separate tool, no copy-paste round trip. Every context switch you introduce is a place adoption dies.

3. A human reviewed and signed before anything was official. The clinician edits the note. Human-in-the-loop was the product shape, not a compliance sticker added at the end.

The one that doesn't port

The clinician was in the room.

They have full context at the moment of review. They know instantly whether the note is right, because they lived the thing being described. That's a property of the domain, not of the software — and it silently carries an enormous amount of weight in making that review meaningful.

Now port that to back-office work. A reviewer is looking at a draft appeal for:

a claim they didn't file
a service they didn't deliver
denied under a policy clause they haven't read today
for a patient they've never met

The exam room handed the clinician context for free. Your review queue gets none of it. And if you hand that person a bare Approve / Reject pair, you have not built a human-in-the-loop system — you've built a queue of people clicking Approve, plus an audit log that makes it look governed.

What you actually have to build

If the reviewer lacks context, the system has to manufacture it. Concretely, what sits next to the draft:

The specific evidence used — the actual claim lines, the actual denial code, not a natural-language summary of them. Summaries hide the thing you need to check.
The policy language cited, quoted and linked. The reviewer should be able to verify the citation, not trust it. This is the single highest-value element and the one most often skipped.
The agent's reasoning, in falsifiable form. "I concluded X because Y" — phrased so a human can actually disagree with a step, not a confidence score.
Deadline and stakes. Reviewers have finite attention. Tell them which items deserve the expensive kind.

The design goal isn't "make review possible." It's "make review possible fast enough that it still happens under real queue pressure." Those are different targets, and only the second one survives contact with production.

Measuring whether review is real

Worth instrumenting: edit rate (what fraction of drafts get modified), time-to-decision distribution (a spike at ~2 seconds means rubber-stamping), and disagreement rate by reviewer. If nobody ever edits anything, your reviewers aren't reviewing — and you'll find that out from an auditor rather than a dashboard.

We build this pattern at IntelliBooks Studio. Happy to get into the evidence-bundling schema or the review-instrumentation design in the comments.

The "95% of AI Pilots Fail" Stat Is About Architecture, Not Models

Vishal Kumar — Wed, 05 Aug 2026 09:11:39 +0000

The most-quoted number in enterprise AI, and what it actually measures

You've seen it: "95% of AI pilots fail." It comes from MIT Project NANDA's July 2025 report, The GenAI Divide: State of AI in Business 2025, which found only 5% of organizations were translating AI pilots into real operational or financial impact.

Most people read that as "the models aren't good enough yet." That's not what the report says. In their words, the divide "does not seem to be driven by model quality or regulation, but seems to be determined by approach." And on the tools themselves: they "fail not because of poor models, but because they don't learn, adapt, or integrate. The lack of memory and feedback loops keeps GenAI stuck as a productivity enhancer, not a workflow transformer."

That reframes the whole thing as an architecture problem. Here's what that means concretely if you're the one building.

Three architectural failures hiding behind "the pilot didn't work"

1. No feedback capture at the decision point. Most deployments generate an output, a human accepts or rejects it, and that judgment evaporates. Nothing is stored about what the human changed or why. You've built a system that can't get better because you never wrote down whether it was right.

The fix is unglamorous: treat the human approval step as a structured data-capture event, not a UI gate. Log the original output, the final output, the delta, and (where you can get it) a reason code. That's a training signal and an audit record in the same row.

2. No durable memory across runs. A stateless call that re-derives context every time can't accumulate anything. Session memory isn't the same as institutional memory — what you want is a persistent, queryable record of past decisions that future runs can actually condition on.

3. Standalone instead of integrated. A chat window next to the workflow is not in the workflow. If a person has to leave the queue they live in, context-switch, prompt something, and paste a result back, you've added a step rather than removed one. The measurable-ROI deployments tend to be the ones where the agent operates inside the existing system of record.

The finding almost nobody quotes

Also in that report: back-office automation delivers stronger ROI than front-office functions, despite 50%+ of AI budgets going to sales and marketing. If you're picking where to spend build effort, that's a useful prior. Back-office work is typically higher-volume, more repeatable, and far easier to measure — which makes both the automation and the ROI case tractable.

In healthcare specifically, that's claims processing, prior authorization, denials and appeals, fraud review. Not the flashy demos — the queues.

Why human-in-the-loop designs sidestep this by accident

Worth naming: MIT studied enterprise GenAI broadly and doesn't endorse any particular approach or vendor. But if you squint at their failure pattern — no memory, no feedback, no integration — a governed agent design avoids all three almost incidentally. The approval step is your feedback capture. The audit trail is your durable memory. And an agent that has to route work to a named reviewer necessarily lives inside the workflow rather than beside it.

We build this pattern at IntelliBooks Studio for healthcare back-office workflows. Happy to get into the feedback-schema design or how we structure the decision log in the comments.

Building Fraud Detection That Separates Flagging From Acting

Vishal Kumar — Tue, 04 Aug 2026 08:50:24 +0000

The number that should make you slow down, not speed up

Healthcare fraud costs the U.S. somewhere between 3% and 10% of total healthcare spending, according to the National Health Care Anti-Fraud Association — at the high end, more than $300 billion a year. A more conservative estimate from the Coalition Against Insurance Fraud puts it around $105 billion annually. Either way it's a huge number, and it's part of why 35% of insurance executives now rank fraud detection among their top AI investment priorities (Deloitte, 2025).

The instinct that number produces is "move fast, automate the response." I think that's backwards, and here's the architecture argument for why.

The asymmetry a lot of fraud-detection systems ignore

A missed fraud case is a cost. A false fraud accusation against a legitimate provider is a different kind of event entirely — reputational damage, a payer relationship at risk, potentially a legal dispute, and it burns your credibility the next time you flag something real. Those failure modes aren't symmetric. A system that treats "flag and act" as one atomic operation is implicitly treating a false positive and a false negative as equally costly. They're not, and pretending they are is what leads teams to over-trust automation on exactly the decision where they shouldn't.

Also worth naming: legitimate providers can look anomalous for entirely legitimate reasons — a sicker patient population, an unusual specialty mix, a billing pattern the model just hasn't seen enough of. Anomaly ≠ fraud, and a model trained mostly on "normal" billing patterns will find a lot of statistically unusual, perfectly legitimate providers.

The architecture: separate flagging from acting

This isn't an argument for slower detection — detection can and should run in real time on every claim. It's an argument for a hard boundary between scoring and acting:

Scoring — every claim gets a fraud-risk score continuously. Fast, automated, no human bottleneck.
Tiering — only the highest-risk tier gets held for review. Everything else flows through normally.
Human review before action — a person sees the case, the evidence, and the model's reasoning before payment is held, a provider is notified, or an investigation is triggered. The model doesn't get to unilaterally do any of those things.
Append-only audit log — what was flagged, what evidence the model cited, who reviewed it, what they decided, and when. Not editable after the fact. If a decision is ever challenged, there's an actual record of who saw what.

The failure mode to design against isn't "too slow to catch fraud" — real-time scoring solves that. It's "acted on a wrong flag with nobody in the loop," which is a much harder mistake to walk back.

Why this matters more here than almost anywhere else in healthcare AI

We build governed agents across claims, prior auth, denials, and fraud detection at IntelliBooks Studio, and fraud is the one domain where we push hardest against full automation — not because detection quality is the problem, but because the cost of being wrong is so lopsided. Happy to get into the scoring-vs-tiering design or the audit-log schema in the comments if useful.

What Building a CMS-0057-F-Compliant Prior Auth System Actually Requires

Vishal Kumar — Mon, 03 Aug 2026 08:55:42 +0000

The compliance date most vendors aren't mentioning

CMS-0057-F isn't a "coming soon" regulation. Since January 1, 2026, impacted payers (Medicare Advantage, State Medicaid, Medicaid MCOs, CHIP MCEs, and QHPs on the federal exchanges) must decide expedited prior-authorization requests within 72 hours, standard requests within 7 calendar days, and every denial has to state a specific reason — not a generic template response. On January 1, 2027, four FHIR-based APIs become required on top of that: Patient Access, Provider Access, Payer-to-Payer, and the Prior Authorization API itself.

That's ~5 months away as I write this. Here's what actually building toward that deadline requires — not the compliance-checklist version, the architecture version.

Where a naive implementation breaks

The easy part is a model that classifies a request as approve/deny. The part that actually determines whether you're compliant is everything downstream of that decision:

Tracking each request against its own deadline (72hr vs 7-day, and the clock starts at intake, not review)
Producing a denial reason that's specific to the case — citing the actual policy clause, not a boilerplate string
Exposing the decision and its status through a FHIR-conformant Prior Authorization API by the 2027 deadline
Keeping a record that survives an audit, not just a database row that can be edited after the fact

The four pieces that make a system actually compliant

1. Deadline-aware routing, not a flat queue. Every incoming request needs its SLA type (expedited/standard) tagged at intake, with the countdown visible to whoever — human or agent — is working the queue. A FIFO queue with no deadline awareness will blow the 72-hour window under any real volume spike.

2. Policy-grounded denial drafting. "Specific reason" means retrieving the actual payer policy behind the code and generating language that cites it — this is a retrieval problem, not a pure generation problem. A generic LLM completion without grounding will drift back toward boilerplate under pressure.

3. A FHIR-shaped API surface, from day one. The Prior Authorization API isn't a nice-to-have add-on for 2027 — if your internal data model doesn't already look like FHIR resources (Claim, ClaimResponse, Task), retrofitting it under deadline pressure next year is much harder than building it FHIR-shaped now.

4. An append-only audit trail. What was decided, by whom (or what), against which policy citation, and when — logged in a way that can't be edited after the fact. This is what turns "we comply" into something you can actually demonstrate.

Why this is worth building now, not in Q4 2026

Five months is not a long runway for four new APIs if the underlying data model isn't already FHIR-shaped. We build this pattern at IntelliBooks Studio for prior-auth and denial workflows specifically — deadline-aware routing, policy-grounded drafting, human sign-off, and an audit trail that holds up to scrutiny. Happy to get into the FHIR resource mapping or the audit-log design in the comments if useful.

What It Actually Takes to Automate a Claims Appeal (Not Just Believe In It)

Vishal Kumar — Sat, 01 Aug 2026 09:03:15 +0000

The stat that matters more than "does AI work"

Two-thirds of healthcare providers (67%) believe AI could improve the claims process. Only 14% actually use it for that purpose (Managed Healthcare Executive). That gap isn't a trust problem — it's an integration problem. Here's the architecture that actually closes it, not the pitch deck version.

Where "AI for claims" usually stops

Most orgs stop at classification: a model flags which denials are worth appealing, maybe drafts boilerplate language. That's the easy 20%. The system rarely does the other 80% — the parts that require state, deadlines, and accountability:

Tracking a payer-specific appeal window (varies by payer, sometimes by plan)
Pulling the specific policy clause a denial cites and drafting a rebuttal against it, not a generic template
Routing the draft to a human with enough runway before the deadline to actually review it
Recording who approved what, and when, in a way that survives an audit

Skip any of those and "AI for claims" stays a demo, not a system a compliance team will sign off on.

The four components that make it real

1. A denial-queue watcher, not a batch job. New denials need to enter the pipeline the moment they're adjudicated, not in a nightly batch — appeal windows are sometimes as short as a few weeks.

2. Policy-grounded drafting. The agent needs to retrieve the actual payer policy language behind a denial code and write the appeal against it, not paraphrase the original claim. This is a retrieval step, not a generation step — the citation has to be real.

3. A human-in-the-loop gate that's actually load-bearing. Not a rubber-stamp UI. The reviewer needs to see the draft, the policy citation, and the deadline together, and be able to edit before it goes out. If the agent can send without a human touching it, you've built something compliance won't approve — and something that will eventually cite the wrong policy at the wrong moment with nobody catching it.

4. An append-only audit trail. What the agent drafted, what a human changed, who approved it, and when it was filed — all logged, none of it editable after the fact. This is what turns "we used AI" into something you can show an auditor.

Why this matters right now

Denial rates keep climbing — 11.65% average initial denial rate in 2025 (HFMA), up from 11.81% in 2024 (Becker's Payer). Appeals work when filed: 57% of denied Medicare Advantage claims get overturned on appeal (Health Affairs). But fewer than 1% of denied ACA marketplace claims are ever appealed at all (KFF). The ceiling on "AI helps with claims" isn't model quality anymore. It's whether anyone built the boring parts — the queue watcher, the policy retrieval, the deadline-aware human gate, the audit log.

We build this pattern at IntelliBooks Studio for claims, prior auth, and denial workflows specifically because the boring parts are where healthcare AI projects actually die. Happy to get into the retrieval or audit-trail design in the comments if useful.

Human-in-the-loop is broken by default — here's the design that actually holds up

Vishal Kumar — Fri, 31 Jul 2026 08:43:41 +0000

"A human approves it" is often treated as a solved-problem checkbox. The 2026 data says the naive version of human-in-the-loop fails predictably, and it fails in a specific, well-documented way.

The failure mode, concretely:

48% of production AI agents run without any security or governance at all (Gravitee, April 2026).
Scale breaks the rest: one documented deployment ran 1.5M agents against 17,000 operators — an 88:1 ratio where real oversight was physically impossible.
Below that scale, a subtler failure: when ~99% of approval requests are routine, humans stop evaluating and start pattern-matching the shape of the dialog box. Named failure modes: approval fatigue, auto-approve habits, "YOLO mode" bypasses.

Why "route everything to a human" doesn't work: it's a throughput problem disguised as a safety feature. A queue of mostly-safe approvals doesn't make the reviewer more careful — it makes them faster and less careful, because the signal-to-noise ratio in the queue is terrible.

The design that holds up: selective escalation.

Classify every decision by confidence and consequence at generation time, not after.
Auto-clear high-confidence, low-consequence, well-cited decisions — but log them fully.
Escalate only genuine ambiguity: low-confidence matches, conflicting policy, first-time scenarios.
Keep the reviewer's queue small enough that each item gets real attention, not a reflex click.

This is the escalation logic behind governed AI agents at IntelliBooks Studio — more at intellibooks.ai/overview.

The 12 fields a defensible AI audit trail actually needs (healthcare edition)

Vishal Kumar — Thu, 30 Jul 2026 08:44:36 +0000

A reference spec, not a pitch: what a defensible AI-decision audit-log entry actually needs to contain, and how long you have to keep it.

The 12-field baseline (2026 guidance):

NTP-synced timestamp, UTC
Unique decision ID
Authenticated human user identity
AI system identity + version
Model identity + version
Inputs, with source attribution
The specific policy/rule invoked
Human-readable reasoning trace
The output
The downstream action taken
Human review/approval, when applicable
Tamper-evident integrity proof

Retention isn't one number: 6 months (EU AI Act) / 1 year (SOC 2) / 6 years (HIPAA-covered workloads). Design for the longest applicable requirement, not the shortest.

Design note: fields 6–8 (inputs with source attribution, policy invoked, reasoning trace) are what actually get scrutinized under challenge — they're the difference between "the model said X" and "the model said X because of Y, sourced from Z." If your schema doesn't capture that chain, the other 9 fields don't save you.

Why this matters now: Colorado, Utah, Texas, and California have active AI enforcement in 2026 — a state-by-state inventory of deployed AI tools is a realistic near-term ask, not a hypothetical. This is the audit-trail schema behind governed AI agents at IntelliBooks Studio — more at intellibooks.ai/overview.

What FDA's shift to continuous AI oversight means for how you architect healthcare agents

Vishal Kumar — Wed, 29 Jul 2026 08:49:30 +0000

Two 2026 regulatory signals are worth designing around if you're building healthcare AI agents, not just reading about after the fact.

Signal one: continuous post-market surveillance, not one-time approval. The FDA is moving AI-enabled devices away from a single approval gate toward ongoing oversight. Architecturally, this means your system needs built-in, exportable evidence of behavior over time — not a one-time validation report. Design the audit trail as a first-class output, not an afterthought bolted on for compliance.

Signal two: clinicians must be able to question the output, not just accept it. Updated Clinical Decision Support guidance requires this explicitly. That's a spec, not a suggestion: every recommendation needs a visible basis (the source/citation), and the interface has to support a real "why did it say that, and do I agree" step — not a black-box output with an accept button.

Context: adoption is real (roughly 80% of hospitals use AI somewhere, though only 22% use domain-specific tools, up from 3% two years ago) and the market is compounding at ~38.62%/year toward $187.69B by 2030. More builders, more scrutiny, both at once.

The design implication is consistent: governed AI agents — grounded, audited, human-checkable by default — aren't just the safer choice, they're increasingly the one the regulatory direction assumes. More at intellibooks.ai/overview.

What a governed claims agent actually automates (and what it deliberately doesn't)

Vishal Kumar — Tue, 28 Jul 2026 08:52:25 +0000

A useful way to scope a claims-automation build: separate the repetitive-but-safe work from the judgment work, and design the interrupt boundary between them explicitly.

What the agent owns:

Claim-status polling. Continuous, high-volume, zero judgment required. (Smilist's public case runs 3,000+/day this way.)
Eligibility re-verification. Check coverage against the current plan before submission, not after a denial.
First-pass appeal drafting. Grounded to the specific denial reason and the payer's policy language — draft only, not send.

What stays behind a human gate:

Anything genuinely ambiguous — conflicting policy language, an edge-case denial reason, a low-confidence match.
The actual submission of an appeal or a request — the agent drafts, a person approves.

The industry context: 80% of health systems were piloting or implementing gen AI for RCM work in 2025 (up from 58% two years prior), and 46% already have it live. The design lesson from that adoption curve: the wins are in the repetitive 80%, not in removing the human from the loop. That's the architecture behind governed AI agents at IntelliBooks Studio — more at intellibooks.ai/overview.